Daniella Beckman - Jun 12, 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role: Director
Signature: /s/ Melissa Masse
Stock symbol: BPMC
Transactions as of: Jun 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/14/2024, 05:38 PM
Previous filing: May 28, 2024
Next filing: Oct 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BPMC	Common Stock	Award	$0	+2.24K	+26.07%	$0.00	10.8K	Jun 12, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BPMC	Stock Option (Right to Buy)	Award	$0	+4.57K		$0.00	4.57K	Jun 12, 2024	Common Stock	4.57K	$106.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders.

Content

The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders.